login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

FDA clears expanded matrix of Glider PTCA balloon catheter


Tuesday, 17 Jul 2012 10:30
Glider
Glider

The US Food and Drug Administration (FDA) has given clearance to TriReme Medical for an expanded matrix of sizes for its Glider PTCA balloon catheter. Glider is now approved for the treatment of lesions in the coronary vasculature in balloon diameters from 1.5 – 3.5mm and in lengths from 4mm to 20mm. 


“Glider provides interventional cardiologists with an entirely new degree of control during the treatment of complex side branches and total occlusions,” said David Rizik, medical director and interventional cardiologist at Scottsdale Heart Group, Scottsdale, USA. “With its torqueable shaft and ultra short 4mm length, I am amased that such a clever design can provide such powerful clinical benefits. Glider has become my ‘go-to’ balloon when I approach the treatment of my most challenging cases.”

“Our recent experience in Europe demonstrates Glider’s ability to outperform conventional ‘best in class’ balloon catheters,” said Eitan Konstantino, president and CEO of TriReme Medical. “TriReme now has three product families that have received regulatory approval in the United States. I am proud of our development team that continues to bring to market ‘out-of-the-box’ solutions to simplify complex interventional procedures.”




Add New Comment

Most popular


US FDA releases draft guidance on real-world evidence and medical device regulation decisions
Wednesday, 27 Jul 2016
According to an email from the consumer watchdog, the document is intended to clarify “how the FDA determines that real-world data may be sufficient for use in premarket and postmarket regulatory ... US FDA releases draft guidance on real-world evidence and medical device regulation decisions

ClearFlow launches smaller PleuraFlow active clearance technology for paediatric use
Wednesday, 27 Jul 2016
After receiving clearance from the US Food & Drug Administration (FDA) earlier this year for expanded Indications for Use with the company’s patented technology, ClearFlow has developed a new model ... ClearFlow launches smaller PleuraFlow active clearance technology for paediatric use

Friday, 29 Jul 2016
Miguel Haime (VA Boston Healthcare System and Boston Medical Center, Boston, USA) is to present an abstract about Somhulation’s DuraGraft during a rapid response session at the 2016 annual meeting of ... Oral abstract on DuraGraft to be presented at EACTS

Features


TAVI durability: A rose by any other name is still a rose
Wednesday, 20 Jul 2016
The data that Dvir presented at EuroPCR, as reported by Cardiovascular News, indicate that there is a significant increase in valve degeneration between five and seven years after a transcatheter ... TAVI durability: A rose by any other name is still a rose

Exploring the borders of TAVI
Monday, 11 Jul 2016
The NOTION 2 trial, which recently enrolled a 64-year-old female with Society of Thoracic Surgeon (STS) score 1.2% as its first patient, is comparing the use of TAVI with the use of surgical aortic ... Exploring the borders of TAVI

Profiles


James Blankenship
Wednesday, 08 Jun 2016
James Blankenship is the 2015–2016 president of SCAI and has been involved with designing and ... James Blankenship

Alexandra Lansky
Monday, 07 Mar 2016
Alexandra Lansky (Director, Heart and Vascular Clinical Research Program, Yale University School of ... Alexandra Lansky

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions